34 results on '"Gelmon, K."'
Search Results
2. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3. Whole-genome and transcriptome analysis enhances precision cancer treatment options
4. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
5. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
6. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
7. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
8. Targeting triple-negative breast cancer: optimising therapeutic outcomes
9. 1st International consensus guidelines for advanced breast cancer (ABC 1)
10. Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
11. Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]
12. Prescribing extended adjuvant letrozole
13. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers
14. 132P Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial
15. 122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib
16. Pharmacologic insights into the future of trastuzumab
17. 411 (PB-044) - Impact of Palbociclib plus Letrozole on Health Related Quality of Life (HRQOL) compared with Letrozole alone in first-line Postmenopausal Patients with ER+ HER2- Metastatic Breast Cancer (MBC): Results from PALOMA-2 Bone Metastases Subgroup
18. 44O - CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors
19. Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259]
20. 512 NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion
21. 7 Outcomes of women with early stage HER-2 over-expressing breast cancer receiving adjuvant trastuzumab: a population based analysis
22. 0170 Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): A multi-centre study from British Columbia
23. Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment
24. Extended adjuvant (EA) endocrine therapy – Tamoxifen (TAM) or an aromatase inhibitor (Al)?
25. 706 POSTER A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies
26. 541 POSTER Pulmonary changes in a randomized phase II study of the mTOR inhibitor RAD001C (Everolimus): NCIC CTG IND.163
27. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
28. Efficacy and safety of three-weekly herceptin with paclitaxel in women with her2-positive metastatic breast cancer: preliminary results of a phase II trial
29. Comparison of outcomes in high risk, locally advanced and inflammatory breast cancer treated with high dose chemotherapy (Quartet) versus standard doxorubicin-based regimens
30. Efficacy of weekly cisplatin-based chemotherapy in recurrent and metastatic head and neck cancer
31. A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer: A study of the NCIC Clinical Trials Group
32. 1070 Phase II trial with docetaxel in patients (PTS) with non small cell lung cancer (NSCLC)
33. 345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)
34. The clinical impact of COVID-19 on patients with cancer in British Columbia: An observational study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.